3 ASX Penny Stocks With Market Caps Under A$31B

The Australian market is poised for a rebound today, following Wall Street's recovery driven by gains in big technology companies and stable treasury yields. Amid these broader market movements, the concept of penny stocks remains an intriguing area for investors seeking opportunities beyond the mainstream. Although considered a niche investment, penny stocks can offer unique growth prospects when backed by solid financials, as we explore three compelling examples on the ASX.

Let's review some notable picks from our screened stocks.

IperionX (ASX:IPX)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: IperionX Limited focuses on developing mineral properties in the United States and has a market capitalization of A$1.09 billion.

Operations: Currently, IperionX Limited does not report any revenue segments.

Market Cap: A$1.09B

IperionX Limited, with a market cap of A$1.09 billion, is a pre-revenue company focusing on developing mineral properties in the United States. Recent developments include securing U.S. Army contracts under the SBIR Phase III IDIQ for titanium defense applications, with potential project orders up to US$99 million. The company has also completed a follow-on equity offering raising US$50 million and acquired critical mineral assets in Tennessee to bolster its resource base. Despite being unprofitable and having increased losses over five years, IperionX maintains strong short-term asset coverage and minimal debt levels relative to cash holdings.

• Take a closer look at IperionX's potential here in our financial health report.
• Gain insights into IperionX's outlook and expected performance with our report on the company's earnings estimates.

Nanosonics (ASX:NAN)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Nanosonics Limited manufactures and commercializes infection control and decontamination products and related technologies across various regions including Australia, North America, Europe, the United Kingdom, the Middle East, and Asia Pacific, with a market cap of A$822.00 million.

Operations: The company's revenue from its healthcare equipment segment is A$203.89 million.

Market Cap: A$822M

Nanosonics Limited, with a market cap of A$822 million, is experiencing mixed financial performance. Despite negative earnings growth of -13.7% over the past year and a reduced net profit margin from 10.4% to 8.7%, the company remains debt-free and has strong asset coverage for both short-term (A$240.7M) and long-term liabilities (A$41.4M). The management team's experience averages 4.3 years, supporting stability in leadership. Recent announcements include a share buyback program worth A$40 million as part of capital management efforts, alongside revenue guidance for fiscal year 2027 projecting growth between 8% to 12%.

• Click here and access our complete financial health analysis report to understand the dynamics of Nanosonics.
• Understand Nanosonics' earnings outlook by examining our growth report.

Sigma Healthcare (ASX:SIG)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Sigma Healthcare Limited operates as a retail pharmacy franchisor and pharmaceutical wholesaler and distributor to community pharmacies in Australia and internationally, with a market cap of A$30.94 billion.

Operations: Sigma Healthcare generates revenue of A$10.83 billion from its healthcare segment.

Market Cap: A$30.94B

Sigma Healthcare has shown robust financial performance, with revenue of A$10.83 billion and net income rising to A$709.18 million for the year ended June 2026. Its earnings growth of 33.8% over the past year surpasses industry averages, although its Return on Equity remains low at 14.2%. The company maintains a satisfactory net debt to equity ratio of 13.3%, with short-term assets exceeding both short and long-term liabilities, indicating strong liquidity positions. Recent strategic decisions include withdrawing from a potential acquisition of Boots UK due to misalignment with investment goals, while maintaining focus on domestic market growth and assessing international opportunities cautiously.

• Click to explore a detailed breakdown of our findings in Sigma Healthcare's financial health report.
• Learn about Sigma Healthcare's future growth trajectory here.

Seize The Opportunity

• Unlock more gems! Our ASX Penny Stocks screener has unearthed 391 more companies for you to explore.Click here to unveil our expertly curated list of 394 ASX Penny Stocks.
• Seeking Other Investments? Rare earth metals are the new gold rush. Find out which 30 stocks are leading the charge.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com